ASX Announcements

Investor presentation, 8 August 2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Quarterly Activities/Appendix 4C Cash Flow Report
Acadia submits Rett Syndrome New Drug Application to the FDA
Neuren commences Phase 2 trial of NNZ-2591 in Angelman syndrome
Notification regarding unquoted securities - NEU
Neuren appoints Chief Medical Officer in United States
Results of Meeting
AGM Chairman's Address & CEO Presentation
Quarterly Activities/Appendix 4C Cash Flow Report